Flutriciclamide (18F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein

التفاصيل البيبلوغرافية
العنوان: Flutriciclamide (18F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein
المؤلفون: Paul Edison, Zhen Fan, Rainer Hinz, Christopher Buckley, Valeria Calsolaro, William Trigg, Rebecca Atkinson, Grazia Daniela Femminella, Adam D. Waldman, David J. Brooks
المساهمون: Fan, Z., Calsolaro, V., Atkinson, R. A., Femminella, G. D., Waldman, A., Buckley, C., Trigg, W., Brooks, D. J., Hinz, R., Edison, P.
المصدر: Europe PubMed Central
Fan, Z, Calsolaro, V, Atkinson, R A, Femminella, G D, Waldman, A, Buckley, C, Trigg, W, Brooks, D J, Hinz, R & Edison, P 2016, ' Flutriciclamide (18F-GE180) PET : First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 57, no. 11, pp. 1753-1759 . https://doi.org/10.2967/jnumed.115.169078Test
بيانات النشر: Society of Nuclear Medicine, 2016.
سنة النشر: 2016
مصطلحات موضوعية: Male, Pilot Projects, 030218 nuclear medicine & medical imaging, 0302 clinical medicine, Reference Values, Reference Value, Tissue Distribution, Whole blood, Aged, 80 and over, Volume of distribution, biology, Chemistry, Brain, First in human, Kinetic model, Middle Aged, Ligand (biochemistry), Third generation, Molecular Imaging, Organ Specificity, Radiopharmaceutical, Female, Human, Carbazoles, Carbazole, Reproducibility of Result, Sensitivity and Specificity, 03 medical and health sciences, Receptors, GABA, GE180, In vivo, Translocator protein, Humans, Pilot Project, Radiology, Nuclear Medicine and imaging, Aged, Flutriciclamide, business.industry, Reproducibility of Results, Biomarker, Pet, Logan analysi, Positron-Emission Tomography, biology.protein, Radiopharmaceuticals, Nuclear medicine, business, Biomarkers, 030217 neurology & neurosurgery
الوصف: Neuroinflammation is associated with neurodegenerative disease. PET radioligands targeting the 18-kDa translocator protein (TSPO) have been used as in vivo markers of neuroinflammation, but there is an urgent need for novel probes with improved signal-to-noise ratio. Flutriciclamide ((18)F-GE180) is a recently developed third-generation TSPO ligand. In this first study, we evaluated the optimum scan duration and kinetic modeling strategies for (18)F-GE180 PET in (older) healthy controls.METHODS: Ten healthy controls, 6 TSPO high-affinity binders, and 4 mixed-affinity binders were recruited. All subjects underwent detailed neuropsychologic tests, MRI, and a 210-min (18)F-GE180 dynamic PET/CT scan using metabolite-corrected arterial plasma input function. We evaluated 5 different kinetic models: irreversible and reversible 2-tissue-compartment models, a reversible 1-tissue model, and 2 models with an extra irreversible vascular compartment. The minimal scan duration was established using 210-min scan data. The feasibility of generating parametric maps was also investigated using graphical analysis.RESULTS: (18)F-GE180 concentration was higher in plasma than in whole blood during the entire scan duration. The volume of distribution (VT) was 0.17 in high-affinity binders and 0.12 in mixed-affinity binders using the kinetic model. The model that best represented brain (18)F-GE180 kinetics across regions was the reversible 2-tissue-compartment model (2TCM4k), and 90 min resulted as the optimum scan length required to obtain stable estimates. Logan graphical analysis with arterial input function gave a VT highly consistent with VT in the kinetic model, which could be used for voxelwise analysis.CONCLUSION: We report for the first time, to our knowledge, the kinetic properties of the novel third-generation TSPO PET ligand (18)F-GE180 in humans: 2TCM4k is the optimal method to quantify the brain uptake, 90 min is the optimal scan length, and the Logan approach could be used to generate parametric maps. Although these control subjects have shown relatively low VT, the methodology presented here forms the basis for quantification for future PET studies using (18)F-GE180 in different pathologies.
وصف الملف: application/pdf
تدمد: 2159-662X
0161-5505
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::250b0e0125c6ef91732b163c6f97f29fTest
https://doi.org/10.2967/jnumed.115.169078Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....250b0e0125c6ef91732b163c6f97f29f
قاعدة البيانات: OpenAIRE